Published • loading... • Updated
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies
Summary by prwire.com.au
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies
SHENZHEN, June 22, 2026 - (ACN Newswire) - China Medical System Holdings Limited (867.HK/8A8.SG) ("CMS", or the "Group") is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the "Product"), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People's Republic of China ("NMPA") and the drug registration certificate was obtained on 22 June 2026. The Pro…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
